Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL.
ERYTHRA-DERM vs ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
Erythromycin ethylsuccinate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation. Sulfisoxazole acetyl is a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
Erythromycin ethylsuccinate (400 mg) and sulfisoxazole acetyl (600 mg) per 5 mL suspension: 2-3 teaspoonfuls (10-15 mL) orally every 6 hours for 10-14 days. Maximum daily dose: 6 g sulfisoxazole.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Erythromycin: terminal half-life of 1.4-2.0 hours in adults; prolonged to 4-6 hours in anuria. Sulfisoxazole: half-life 4.5-7 hours in adults; increased in renal impairment. The combination's clinical context warrants dosing interval adjustments in renal dysfunction.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Erythromycin ethylsuccinate is primarily excreted in bile (up to 80% as unchanged drug), with about 12-15% eliminated renally. Sulfisoxazole acetyl is renally excreted, with approximately 85% of the dose appearing in urine as acetylated and deacetylated metabolites. Fecal elimination accounts for less than 10% of sulfisoxazole.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic